Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Olaparib has been proven for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This meta-analysis aims to comprehensively evaluate the efficacy and safety of the combination of olaparib and abiraterone in patients with mCRPC. METHODS: The literature in PubMed, Emb...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Zhanyang, Zhu, Bukun, Xu, Hong, Chen, Lixin, Song, Xiaoyun, Wang, Yu, Wang, Rui, Zheng, Jinzhou, Qiu, Yunhua, Yang, Jianfeng, Shi, Youyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587563/
https://www.ncbi.nlm.nih.gov/pubmed/37869079
http://dx.doi.org/10.3389/fonc.2023.1265276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587563/
https://www.ncbi.nlm.nih.gov/pubmed/37869079
http://dx.doi.org/10.3389/fonc.2023.1265276

Ejemplares similares